Your browser is no longer supported. Please, upgrade your browser.
Settings
BNTX [NASD]
BioNTech SE
Index- P/E- EPS (ttm)- Insider Own1.18% Shs Outstand238.67M Perf Week-5.76%
Market Cap25.56B Forward P/E6.09 EPS next Y17.90 Insider Trans0.00% Shs Float223.06M Perf Month2.89%
Income- PEG- EPS next Q-0.13 Inst Own9.60% Short Float1.66% Perf Quarter7.03%
Sales- P/S- EPS this Y-300.50% Inst Trans-8.96% Short Ratio1.13 Perf Half Y60.57%
Book/sh4.70 P/B23.20 EPS next Y1136.60% ROA- Target Price119.55 Perf Year221.81%
Cash/sh5.20 P/C20.97 EPS next 5Y- ROE- 52W Range28.00 - 131.00 Perf YTD33.75%
Dividend- P/FCF- EPS past 5Y- ROI-32.00% 52W High-16.77% Beta-
Dividend %- Quick Ratio4.00 Sales past 5Y- Gross Margin- 52W Low289.39% ATR5.33
Employees1800 Current Ratio4.10 Sales Q/Q30.10% Oper. Margin- RSI (14)44.87 Volatility5.33% 4.33%
OptionableYes Debt/Eq0.34 EPS Q/Q-119.50% Profit Margin- Rel Volume0.31 Prev Close112.33
ShortableYes LT Debt/Eq0.19 Earnings- Payout- Avg Volume3.28M Price109.03
Recom2.20 SMA20-5.69% SMA502.45% SMA20030.26% Volume1,024,936 Change-2.94%
Dec-01-20Downgrade BofA Securities Buy → Neutral $123 → $126
Aug-03-20Resumed Berenberg Buy $98
Jul-21-20Upgrade BofA Securities Neutral → Buy $71 → $105
Jun-30-20Downgrade H.C. Wainwright Buy → Neutral
May-19-20Upgrade H.C. Wainwright Neutral → Buy $48 → $69
Apr-28-20Downgrade BofA/Merrill Buy → Neutral $46 → $51
Mar-18-20Downgrade JP Morgan Overweight → Neutral $23 → $33
Mar-09-20Initiated H.C. Wainwright Neutral $30
Jan-24-20Downgrade SVB Leerink Outperform → Mkt Perform
Jan-22-20Downgrade UBS Buy → Neutral $35
Nov-05-19Initiated Wolfe Research Outperform
Nov-04-19Initiated UBS Buy $21
Nov-04-19Initiated SVB Leerink Outperform
Nov-04-19Initiated JP Morgan Overweight $23
Nov-04-19Initiated Canaccord Genuity Buy $22
Nov-04-19Initiated BofA/Merrill Buy $21
Nov-04-19Initiated Berenberg Buy $25
Feb-26-21 08:56PM  
07:24PM  
05:38PM  
05:08PM  
05:06PM  
10:37AM  
07:30AM  
06:30AM  
06:00AM  
Feb-25-21 04:52PM  
04:42PM  
12:40PM  
10:33AM  
08:10AM  
08:08AM  
07:39AM  
07:03AM  
07:03AM  
06:45AM  
06:45AM  
06:45AM  
Feb-24-21 06:06PM  
04:42PM  
04:37PM  
04:12PM  
04:10PM  
10:29AM  
Feb-23-21 03:54PM  
11:57AM  
10:55AM  
10:50AM  
05:51AM  
02:49AM  
Feb-22-21 04:55PM  
02:55PM  
07:46AM  
07:09AM  
06:07AM  
05:28AM  
Feb-21-21 09:00AM  
Feb-19-21 07:45PM  
01:58PM  
12:48PM  
12:43PM  
12:14PM  
12:09PM  
10:54AM  
10:45AM  
09:25AM  
08:22AM  
07:37AM  
07:28AM  
07:07AM  
Feb-18-21 06:00PM  
04:47PM  
04:26PM  
01:45PM  
01:30PM  
11:08AM  
11:07AM  
10:52AM  
09:25AM  
07:26AM  
04:15AM  
Feb-17-21 07:28PM  
05:34PM  
05:13PM  
10:46AM  
09:43AM  
09:15AM  
07:26AM  
06:46AM  
06:46AM  
06:20AM  
06:13AM  
04:00AM  
01:06AM  
Feb-16-21 10:46AM  
08:05AM  
07:47AM  
07:00AM  
Feb-15-21 09:34PM  
12:52PM  
Feb-14-21 05:12AM  
Feb-12-21 05:21PM  
03:22PM  
08:56AM  
08:30AM  
07:00AM  
Feb-11-21 05:50PM  
07:55AM  
06:20AM  
Feb-10-21 01:50PM  
10:26AM  
08:19AM  
07:08AM  
04:58AM  
03:00AM  
02:00AM  
Feb-09-21 06:03AM  
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in developing FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/II trial for prostate cancer; BNT113, which is in Phase I trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116, which is in preclinical trail for non-small cell lung cancer. It also develops neo-antigen specific immunotherapies, such as RO7198457, which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT152 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT212 for pancreatic and other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops MVT-5873, an IgG1 monoclonal antibody, which is in Phase I/II clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Genevant Sciences GmbH; Eli Lilly and Company; Bayer AG; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; Regeneron Pharmaceuticals, Inc.; and InstaDeep Ltd. The company was founded in 2008 and is headquartered in Mainz, Germany.